Drug-eluting stent study
This article was originally published in The Gray Sheet
Executive Summary
Guidant has received FDA permission to expand the SPIRIT III trial of its Xience V everolimus-eluting stent to the full cohort of 1,292 patients at up to 80 sites. The trial compares the Xience V, built on Guidant's cobalt-chromium Multi-Link Vision platform, with Boston Scientific's Taxus paclitaxel-eluting stent. The trial began in May (1"The Gray Sheet" May 9, 2005, p. 12)...
You may also be interested in...
Guidant’s SPIRIT
Over 300 patients are enrolled in the SPIRIT II and SPIRIT III European drug-eluting stent clinical trials, triggering a $60 mil. milestone payment to drug-supplier Novartis, Guidant announces Sept. 21. The trial compares Guidant's Xience V everolimus-eluting stent to Boston Scientific's Taxus paclitaxel-eluting stent. In June, FDA approved an expansion of the SPIRIT III trial to include 1,292 patients at up to 80 sites (1"The Gray Sheet" Aug. 29, 2005, In Brief). The notified body that will review Xience for CE Mark completed its inspection of the firm's Temecula, Calif. facility...
J&J Looks To Broaden Spine Offerings, Considers DTC Ads For Charité
Johnson & Johnson is pursuing alternate spinal technologies to address Charité artificial lumbar disc limitations, which are hindering adoption of the device as a stand-alone, total spine treatment
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”